Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022
Atea Pharmaceuticals (AVIR) announced a live conference call for August 8, 2022, at 4:30 p.m. ET to discuss its Q2 financial results and provide a business update. The company focuses on developing oral antiviral therapies for severe viral diseases, including COVID-19 and hepatitis C. This event will be accessible via registration and a live webcast on their investor relations website. Atea emphasizes its commitment to advancing its nucleos(t)ide prodrug platform for treating RNA viruses. They also caution about risks associated with forward-looking statements.
- Atea continues to develop its proprietary nucleos(t)ide prodrug platform for antiviral therapies.
- Focus on severe viral infections indicates potential for significant market demand.
- No specific financial results or metrics were disclosed, which may leave investors uncertain about performance.
BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2022, and to provide a business update.
To access the live conference call, participants must register here to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. A live webcast of the call will also be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at https://ir.ateapharma.com. An archived webcast will be available on Atea Pharmaceuticals’ website approximately two hours after the conference call and will be available for at least ninety days.
About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with severe diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Currently, Atea is focused on the development of orally-available antiviral agents for difficult-to-treat, severe viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus (HCV), dengue virus and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing of Atea’s earnings call for the quarter ended June 30, 2022. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com
FAQ
When will Atea Pharmaceuticals report its Q2 financial results?
What is the focus of Atea Pharmaceuticals in their drug development?
How can investors access Atea Pharmaceuticals' conference call?
What are the key products in Atea Pharmaceuticals' pipeline?
